Karyopharm Therapeutics (KPTI) Gains from Investment Securities (2012 - 2025)
Karyopharm Therapeutics (KPTI) reported Gains from Investment Securities of $271787.0 for Q4 2025, down 36.12% on a YoY basis from $425479.0 in Q4 2024, and down 36.12% quarter-over-quarter from $425479.0 in Q4 2024.
Karyopharm Therapeutics (KPTI) Gains from Investment Securities (2012 - 2025) Analysis & Trends
Karyopharm Therapeutics has reported Gains from Investment Securities for 14 years, with the latest figure at $271787.0 in Q4 2025.
- For the quarter ending Q4 2025, Gains from Investment Securities fell 36.12% year-over-year to $271787.0; the trailing twelve-month figure through Dec 2025 stood at $271787.0 (down 36.12% YoY), and the FY2025 full-year result was $271787.0, down 36.12% from the prior year.
- Gains from Investment Securities for Q4 2025 stood at $271787.0, down from $425479.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $425479.0 in Q4 2024, with the low at -$231000.0 in Q2 2021.
- Historically, Gains from Investment Securities has averaged $66938.8 across 5 years, with a median of $2000.0 in 2022.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities sank 300.0% — and 2024, when it soared 14082.63%.
- Karyopharm Therapeutics' Gains from Investment Securities stood at $177000.0 in 2021, then slumped by 101.69% to -$3000.0 in 2022, then surged by 200.0% to $3000.0 in 2023, then soared by 14082.63% to $425479.0 in 2024, then plunged by 36.12% to $271787.0 in 2025.
- The last three Gains from Investment Securities figures came in at $271787.0 (Q4 2025), $425479.0 (Q4 2024), and $3000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Karyopharm Therapeutics | 95.31 Mn | 31.56 Mn | 32.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 271,787.00 |
| Dec 31, 2025 | 271,787.00 |
| Dec 31, 2024 | 425,479.00 |
| Dec 31, 2024 | 425,479.00 |
| Dec 31, 2023 | 3,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Mar 31, 2023 | -4,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Sep 30, 2022 | -1,000.00 |
| Jun 30, 2022 | 2,000.00 |
| Jun 30, 2022 | 2,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Dec 31, 2021 | 177,000.00 |
| Dec 31, 2021 | 177,000.00 |